Cristina Alonso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3362638/publications.pdf

Version: 2024-02-01

30 papers	1,730 citations	361296 20 h-index	501076 28 g-index
32 all docs	32 docs citations	32 times ranked	2753 citing authors

#	Article	IF	Citations
1	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology, 2017, 152, 1449-1461.e7.	0.6	209
2	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 835-856.	8.2	183
3	Liquid Chromatographyâ^'Mass Spectrometry-Based Parallel Metabolic Profiling of Human and Mouse Model Serum Reveals Putative Biomarkers Associated with the Progression of Nonalcoholic Fatty Liver Disease. Journal of Proteome Research, 2010, 9, 4501-4512.	1.8	144
4	Metabolomicâ€based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology Communications, 2018, 2, 807-820.	2.0	117
5	Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2019, 25, 3009-3020.	1.4	115
6	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 547-562.	3.6	112
7	Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology, 2013, 58, 1296-1305.	3.6	100
8	Enhancing metabolomics research through data mining. Journal of Proteomics, 2015, 127, 275-288.	1.2	87
9	Role of aramchol in steatohepatitis and fibrosis in mice. Hepatology Communications, 2017, 1, 911-927.	2.0	84
10	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. Cell Metabolism, 2020, 31, 605-622.e10.	7.2	68
11	Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology, 2020, 159, 999-1014.e9.	0.6	59
12	Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers, 2020, 12, 1142.	1.7	53
13	Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlrâ€/â€Leiden Mice. Hepatology Communications, 2018, 2, 1513-1532.	2.0	49
14	The Lâ€±â€Lysophosphatidylinositol/G Proteinâ€“Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis. Hepatology, 2021, 73, 606-624.	3.6	42
15	Use of a metabolomic approach to nonâ€invasively diagnose nonâ€alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 1702-1709.	2.2	39
16	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers, 2020, 12, 1644.	1.7	38
17	Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. Journal of Hepatology, 2022, 77, 15-28.	1.8	31
18	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	3.6	31

#	Article	IF	Citations
19	Deciphering non-alcoholic fatty liver disease through metabolomics. Biochemical Society Transactions, 2014, 42, 1447-1452.	1.6	26
20	The fatty acids of sphingomyelins and ceramides in mammalian tissues and cultured cells: Biophysical and physiological implications. Chemistry and Physics of Lipids, 2018, 217, 29-34.	1.5	26
21	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers, 2020, 12, 1433.	1.7	20
22	Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer. Cancers, 2018, 10, 300.	1.7	18
23	Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer. Cancers, 2021, 13, 6216.	1.7	16
24	Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. Hepatology Communications, 2020, 4, 193-207.	2.0	15
25	A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. Journal of Hepatology, 2022, 76, 800-811.	1.8	15
26	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl4-Induced Liver Fibrosis. International Journal of Molecular Sciences, 2020, 21, 9043.	1.8	12
27	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International, 2020, 40, 2860-2876.	1.9	12
28	Emerging Circulating Biomarkers for TheÂDiagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. , 2019, , 423-448.		4
29	Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development, 2019, 4, 283-297.	0.4	1
30	Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c. , 2019, , 405-421.		0